InflaRx Discontinues Pyoderma Gangrenosum Trial, Shifts Focus to INF904 with Summer 2025 Data Expected
InflaRx (NASDAQ:IFRX) is one of the best penny stocks under $1 to buy now.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Suvretta Capital Management Aaron Cowen | 6,483,910 | $8,688,439 | 0.22% | |
| 2. | 683 Capital Partners Ari Zweiman | 2,250,000 | $3,015,000 | -10% | 0.16% |
| 3. | RA Capital Management Peter Kolchinsky | 1,973,233 | $2,644,132 | 0.03% | |
| 4. | Eversept Partners Kamran Moghtaderi | 1,730,635 | $2,319,051 | +6% | 0.16% |
| 5. | Ikarian Capital Neil Shahrestani | 722,066 | $967,568 | +3% | 0.1% |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,475,000 | $3,316,500 | 0% | |
| 2. | 626,599 | $839,643 | 0% | |
| 3. | 457,899 | $613,585 | 0% | |
| 4. | 175,114 | $234,653 | 0% | |
| 5. | 142,055 | $190,354 | 0% |